Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KN5508
- Development stage
- Preclinical
- Lead developer
- Rui Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
KN5508 is an investigational chimeric antigen receptor-engineered natural killer (CAR-NK) cell therapy being developed by Rui Therapeutics (Shenzhen Enrui Kainuo Biotechnology Co., Ltd.). The therapy is part of a proprietary platform designed to enhance the innate tumor-killing capabilities of NK cells by engineering them to express specific receptors. While the specific molecular target and primary disease indication for KN5508 have not been publicly disclosed, it is positioned as a first-in-class candidate within the company's pipeline. It is currently in the early stages of preclinical research and development.
02
Targets
Beyond the preview
Go deeper on KN5508.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KN5508.